PDS Biotechnology Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from PDS Biotechnology Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-5.4×Operating cash was negative last year, while some debt falls due within a year.
Higher than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 53% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
PDS Biotechnology Corporation made a loss over the last year. PDS Biotechnology Corporation owes $1.41 for every $1 it owns. PDS Biotechnology Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPDS Biotechnology Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-23.48PDS Biotechnology Corporation's book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$84 MThe total market value of all of PDS Biotechnology Corporation's shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativePDS Biotechnology Corporation's net worth is negative ($4 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-544.0%PDS Biotechnology Corporation lost 544.0% of its shareholders' money over the last year, lower than 94% of Healthcare companies in United States.
Owes vs Owns
1.41×PDS Biotechnology Corporation owes $1.41 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NonePDS Biotechnology Corporation does not currently pay a dividend.
Profit growth
LossPDS Biotechnology Corporation made a loss in each of the last two years.
Interest cover
Not coveredPDS Biotechnology Corporation's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashPDS Biotechnology Corporation held $10 M more cash than debt (net cash) at Dec 2025.
Questions
What is PDS Biotechnology Corporation's return on equity?
PDS Biotechnology Corporation lost 544.0% of its shareholders' money over the last year, lower than 94% of Healthcare companies in United States.
How much does PDS Biotechnology Corporation owe compared with what it owns?
PDS Biotechnology Corporation owes $1.41 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does PDS Biotechnology Corporation pay a dividend?
No. PDS Biotechnology Corporation does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.